SAN DIEGO--(BUSINESS WIRE)--Genome Insight, a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, today announced that it has closed a $23 million in a Series B-2 investment in its latest funding round. The round was joined by Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation. Existing investors participated in this round. This round follows a Series B investment in 2022 that also raised $23 million.
This investment will support Genome Insight’s pursuit of bringing whole-genome based precision diagnostics to routine clinical care. Earlier this year, the company announced the launch of CancerVision, a test that utilizes whole genome sequencing to offer precise, timely, and medical relevant information that assists in making individualized healthcare decision in cancer. CancerVision integrates advanced bioinformatics and computational techniques to determine whole-genome mutational profiles of individual cancer patients. The information is analyzed and curated for physicians in an easy-to-use format that captures the most relevant and actionable insights for each patient.
"Genomic data has the potential to unlock a new era in healthcare. We envision a future where genomic information is integral to standard patient care," says Young Seok Ju, the Founder and CEO at Genome Insight.
About CancerVision
CancerVision was designed to empower healthcare providers with the information necessary to make informed decisions tailored to an individual's unique genomic profile. Whole genome sequencing (WGS) provides a more complete view (>99%) of a cancer's genetic make-up than any other test currently available, including targeted panels and whole exome testing. CancerVision can provide detailed information about genomic mutations and other biomarkers that may be driving a patient's cancer. This information can support healthcare providers in identifying potential treatment approaches, such as targeted therapies and clinical trials, tailored to an individual's specific cancer type and genetic makeup.
About Genome Insight
Genome Insight, Inc. is a global team, with headquarters in San Diego, California. The company was brought to fruition by physicians with a common vision to deliver unparalleled bioinformatics that merges whole-genome and patient data with to deliver first-in-class research and discovery, precision diagnostics and treatments. The company’s mission is to improve how patients are diagnosed and treated, by unlocking the full potential of personalized genomic data. To learn more, please visit https://genomeinsight.net
责任编辑: admin
珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!
焦点新闻
热图要闻
热门排行
- PLDA宣布推出Robust Verification Toolset,以提
- Ludovic Blanquet Joins smartTrade as Chief Pro
- Wolters Kluwer FRR Launches OneSumX for Risk M
- 香港旅遊發展局訂立統一衞生防疫指引 向旅客傳遞
- Nanboya香港辦事處遷至佐敦,首個海外採購辦公室
- GSMA Announces Date Changes for its MWC21 Seri
- 罗克韦尔自动化收购网络安全公司
- Standard Digital Group Is Now Accepting Online
- Nanboya香港辦事處遷至佐敦,首個海外採購辦公室
- Standard Digital Group Is Now Accepting Online